Sereda Alexey D, Kazakova Anna S, Namsrayn Sanzhi G, Vlasov Mikhail E, Sindryakova Irina P, Kolbasov Denis V
Federal Research Center for Virology and Microbiology (FRCVM), 601125 Volginsky, Petushki Area, Vladimir Region, Russia.
Vaccines (Basel). 2023 May 21;11(5):1007. doi: 10.3390/vaccines11051007.
Understanding the immunological mechanisms of protection and the viral proteins involved in the induction of a protective immune response to the African swine fever virus (ASFV) is still limited. In the last years, the CD2v protein (gp110-140) of the ASFV has been proven to be a serotype-specific protein. Current work is devoted to the investigation of the possibility of creating protection against virulent ASFV strain Mozambique-78 (seroimmunotype III) in pigs previously vaccinated with vaccine strain FK-32/135 (seroimmunotype IV) and then immunized with the pUBB76A_CD2v plasmid, containing a chimeric nucleotide sequence from the CD2v protein gene (EP402R, nucleotides from 49 to 651) from the MK-200 strain (seroimmunotype III). Vaccination with the ASFV vaccine strain FK-32/135 protects pigs from the disease caused by the strain with homologous seroimmunotype-France-32 (seroimmunotype IV). Our attempt to create balanced protection against virulent strain Mozambique-78 (seroimmunotype III) by induction of both humoral factors of immunity (by vaccination with strain FK-32/135 of seroimmunotype IV) and serotype-specific cellular immunity (by immunization with the plasmid pUBB76A_CD2v of seroimmunotype III) was unsuccessful.
目前对于非洲猪瘟病毒（ASFV）保护性免疫机制以及诱导保护性免疫反应所涉及的病毒蛋白的了解仍然有限。近年来，已证实ASFV的CD2v蛋白（gp110 - 140）是一种血清型特异性蛋白。当前的研究致力于探讨在先前接种过疫苗株FK - 32/135（血清免疫型IV）的猪中，通过用包含来自MK - 200株（血清免疫型III）的CD2v蛋白基因（EP402R，核苷酸49至651）的嵌合核苷酸序列的pUBB76A_CD2v质粒进行免疫，来构建针对强毒株莫桑比克 - 78（血清免疫型III）的保护力。用ASFV疫苗株FK - 32/135进行疫苗接种可保护猪免受同源血清免疫型毒株法国 - 32（血清免疫型IV）所引起的疾病。我们试图通过诱导体液免疫因子（用血清免疫型IV的疫苗株FK - 32/135进行疫苗接种）和血清型特异性细胞免疫（用血清免疫型III的质粒pUBB76A_CD2v进行免疫）来构建针对强毒株莫桑比克 - 78（血清免疫型III）的平衡保护力，但未成功。
